Files and links (1)
Accepted (AM)Open Access (License Unspecified), Open
Journal article
Development of a novel inducer for EBV lytic therapy
Bioorganic & medicinal chemistry letters, v 29(16), pp 2259-2264
15 Aug 2019
PMID: 31255485
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Preliminary SAR studies and in vivo reactivation of EBV in SNU719 gastric carcinoma and AGS-Akata gastric carcinoma xenograft mouse model.
Epstein-Barr virus (EBV) is a human herpesvirus that infects over 90% of the world's population that persists as a latent infection in various lymphoid and epithelial malignancies. The total number of EBV associated malignancies is estimated to exceed 200,000 new cancers per year. Current chemotherapeutic treatments of EBV-positive cancers include broad-spectrum cytotoxic drugs that ignore the EBV positive status of tumors and have limited safety and selectivity. In an effort to develop new and more efficacious molecules for inducing EBV reactivation, we have developed high-throughput screening assays to identify a class of small molecules (referred to as the C60 series) that efficiently activate the EBV lytic cycle in multiple latency types, including lymphoblastoid and nasopharyngeal carcinoma cell lines. In this paper we report our preliminary structure activity relationship studies and demonstrate reactivation of EBV in the SNU719 gastric carcinoma mouse model and the AGS-Akata gastric carcinoma mouse model.
Metrics
Details
- Title
- Development of a novel inducer for EBV lytic therapy
- Creators
- Nadezhda Tikhmyanova - The Wistar InstituteNicholas Paparoidamis - Drexel University, ChemistryJames Romero-Masters - University of Wisconsin–MadisonXin Feng - Department of Pharmacology, School of Medicine, Drexel University, Philadelphia, PA 19104, United StatesFarheen Sultana Mohammed - The Wistar InstitutePoli Adi Narayana Reddy - The Wistar Institute, Philadelphia, PA 19104, United StatesShannon C. Kenney - University of Wisconsin–MadisonPaul M. Lieberman - The Wistar InstituteJoseph M. Salvino - The Wistar Institute, Philadelphia, PA 19104, United States
- Publication Details
- Bioorganic & medicinal chemistry letters, v 29(16), pp 2259-2264
- Publisher
- Elsevier Ltd
- Number of pages
- 6
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pharmacology and Physiology; Chemistry
- Web of Science ID
- WOS:000480235700045
- Scopus ID
- 2-s2.0-85067989475
- Other Identifier
- 991021860806404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Chemistry, Medicinal
- Chemistry, Organic